IBIO, INC. Debt Securities, Available-for-sale, Unrealized Loss
IBIO, INC. (IBIO) reported Debt Securities, Available-for-sale, Unrealized Loss of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2023-11-14
- IBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- IBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- IBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2023-03-31 was $113.00K, a 9.71% increase year-over-year.
- IBIO, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-12-31 was $36.00K, a 33.33% increase year-over-year.
- IBIO, INC. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $159.00K, a 6.00% increase from fiscal 2022.
- IBIO, INC. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $150.00K, a 417.24% increase from fiscal 2021.
- IBIO, INC. debt securities, available-for-sale, unrealized loss for fiscal 2021 was $29.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $113.00K derived: sum of 3 quarters · filed 2023-11-14 | $149.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-27 | $113.00K derived: sum of 2 quarters · filed 2023-09-27 | $149.00K derived: sum of 3 quarters · filed 2023-09-27 | $159.00K 10-K · filed 2023-09-27 |
| 2023-03-31 | $113.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-05-15 | $149.00K derived: sum of 2 quarters · filed 2023-05-19 | $159.00K 10-Q · filed 2023-05-15 | $178.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $36.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-05-19 | $46.00K 10-Q/A · filed 2023-05-19 | $65.00K derived: sum of 3 quarters · filed 2023-11-14 | $168.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-09-30 | $10.00K 10-Q · filed 2023-11-14 | $29.00K derived: sum of 2 quarters · filed 2023-11-14 | $132.00K derived: sum of 3 quarters · filed 2023-11-14 | $159.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-27 | $122.00K derived: sum of 2 quarters · filed 2023-09-27 | $149.00K derived: sum of 3 quarters · filed 2023-09-27 | $150.00K 10-K · filed 2023-09-27 |
| 2022-03-31 | $103.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-05-15 | $130.00K derived: sum of 2 quarters · filed 2023-05-19 | $131.00K 10-Q · filed 2023-05-15 | $124.00K derived: sum of 4 quarters · filed 2023-05-19 |
| 2021-12-31 | $27.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-05-19 | $28.00K 10-Q/A · filed 2023-05-19 | $21.00K derived: sum of 3 quarters · filed 2023-05-19 | $37.00K derived: sum of 4 quarters · filed 2023-05-19 |
| 2021-09-30 | $1.00K 10-Q · filed 2022-11-14 | -$6.00K derived: sum of 2 quarters · filed 2022-11-14 | $10.00K derived: sum of 3 quarters · filed 2022-11-14 | $30.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-11 | $9.00K derived: sum of 2 quarters · filed 2022-10-11 | $29.00K derived: sum of 3 quarters · filed 2022-10-11 | $29.00K 10-K · filed 2022-10-11 |
| 2021-03-31 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-12 | $36.00K derived: sum of 2 quarters · filed 2022-05-12 | $36.00K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $20.00K 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $0.00 10-Q · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |